Back to News & Events

CFB Client Secures $3M Public and Private Investment

November 14, 2017

Codagenix, Inc., a clinical stage, venture and public-sector-funded small business, announced it has secured an additional $3M in funding in support of its live-attenuated Respiratory Syncytial Virus (RSV) vaccine candidate that was developed in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH.

The public funding to Codagenix is via a Phase II SBIR grant for $1.5M to support the pre-clinical manufacturing of the vaccine candidate. The private funding of $1.5M was provided by TopSpin Partners to support a Phase I trial to demonstrate safety and immunogenicity in aged volunteers. The two funding source were not linked; however, both are dedicated to supporting Codagneix’s RSV vaccine through a Phase I trial. Clinical Trial material of Codagenix RSV Vaccine candidate is currently being manufactured with a Phase I targeted for Q3- or Q4-2018.

“Codagenix is an incredible example of a company rooting in our expanding bioecosystem, growing from a startup out of Stony Brook University into a clinical stage company” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is proud to provide ongoing support for the work they are doing through our various programs including the Applied Research and Development awards and the Long Island Bioscience Hub funding initiatives.

“We are wrapping up a Phase I with our live-attenuated Influenza Vaccine in Q1-2018 and are very much looking forward to adding a second clinical-stage compound to our pipeline with RSV,” stated Codegenix COO J. Robert Coleman. “We are grateful to our investors and partners like the Center for Biotechnology that understand our vision and continually support our development at these early stages. We are demonstrating that our platform provides a rational means to design vaccines against a range targets – yielding candidates suitable for full clinical development.”

Codagenix has raised a total of $10M since 2015 – with its influenza vaccine candidate currently in Phase I and a pre-clinical pipeline that includes Zika, Dengue, and Agricultural targets in addition to RSV.

RSV is a virus that targets newborns and the elderly, with an estimated market size of $2 Billion for a potential RSV vaccine.

About Codagenix Inc.
Codagenix Inc., a biotechnology company on Long Island, New York, is developing live attenuated vaccines using a “disruptive” software-based rational design algorithm that is unlike previous vaccine “platforms”. By leveraging the redundancy in the genetic code (various codons exist at the gene level to encode the same amino acid at the protein level), the Codagenix algorithm re-structures viral genomes into a sub-optimal genetic code. The so-called “deoptimized” viruses have resulted in highly attenuated vaccine strains that are effective at greatly reduced doses, because they present every antigen of the pathogen, while being 100% identical to the target pathogen at the protein level. The Codagenix pipeline of vaccines includes Influenza, respiratory syncytial virus (RSV), Zika, Dengue, foot-and-mouth disease virus (FMDV), pathogenic E. coli, and other pathogens.

Codagenix has also been supported the Center for Biotechnology at Stony brook University which is a New York State Center for Advanced Technology and NIH-designated Research, Evaluation and Commercialization Hub (REACH)

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.





The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development. 





Read more about IAMBIC and their recent funding here.


                    [post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
                    [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-19 10:50:15
                    [post_modified_gmt] => 2024-11-19 15:50:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4439
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 3046
                    [post_author] => 3
                    [post_date] => 2018-08-22 20:10:08
                    [post_date_gmt] => 2018-08-22 20:10:08
                    [post_content] => Seasoned Industry Veterans Join Long Island Bioscience Hub’s BioEntrepreneur-in Residence Initiative

The Long Island Bioscience Hub, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, announced the appointment of Dr. Boris Shor and Mr. Peter Young as its newest BioEntrepreneurs-In-Residence (BEIRs). Dr. Shor and Mr. Young have extensive bioscience industry experience affording them unique perspectives in the role of Bio Entrepreneur-in-Residence. Each will work with the Center for Biotechnology to identify commercially promising academic technologies that have the potential to support company formation.

Dr. Shor has nearly 15 years of experience in leading oncology programs and external R&D partnerships at the large pharmas and biotech companies, with specific focus on preclinical development of small molecule kinase inhibitors and biologics. Previously at Pfizer, Dr. Shor led internal and external collaboration project teams to develop novel antibody-drug conjugates and supported BLA filing for Inotuzumab, which was approved for the treatment of leukemia in 2017. Prior to that, he was a project team leader at the Oncology Unit of Wyeth, managing the discovery of novel kinase inhibitors for the treatment of cancer. He currently serves on the executive management team of early-stage biotech companies and is a founder of BioIDEA, a biotech pitch event in New York City. Dr. Shor received a Ph.D. in Molecular and Cell Biology at the State University of New York Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Pfizer.

Mr. Young is an experienced life science industry consultant with over thirty-five years experience and currently serves as an executive-in-residence with Pappas Capital, where he leads the firm’s initiatives in translational research. He also serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research and the Long Island Bioscience Hub External Review Board. He is a past member of the BIO board and chairman of NCBIO, the North Carolina industry trade association. Mr. Young earned a BA in History and an MBA from Indiana University.

“We couldn’t be more delighted to add Boris and Peter to the Center for Biotechnology’s roster of BioEntrepreneurs-in-Residence. The ongoing expansion of the BioEntrepreneur-in-Residence program is critical for the continued development of the bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said. “The attraction and retention of skilled bioscience management talent is an important component of ensuring companies can be launched and also grow here.”

“I am thrilled to join the Center for Biotechnology as a BioEntrepreneur-in-Residence” Dr. Shor stated, “and I have already begun the work of assessing technologies and building a company. I appreciate the resources the Center for Biotechnology offers through their many programs not only to me, but to emerging companies throughout New York.”

“Having worked with the Center for Biotechnology as an advisor for several years, I am pleased to formally join the Center as BioEntrepreneur-in-Residence” Peter Young stated. “There is an incredible amount of activity related to bioscience development currently taking place right now in the region, and the Center's many entrepreneurial programs provide a great springboard for significant industry expansion - I'm thrilled to be a part of it.”

In their roles as BEIRs, Dr. Shor and Mr. Young will work to identify a technology or technologies from within partner institutions that will create the foundation for licensing and company formation. They will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment.

Dr. Shor and Mr. Young join the eight BEIRs already working with the Center for Biotechnology who collectively have launched ten new companies in the last five years.
                    [post_title] => Long Island Bioscience Hub Appoints Additional BioEntrepreneurs-In-Residence
                    [post_excerpt] => Seasoned Industry Veterans Join Long Island Bioscience Hub’s BioEntrepreneur-in-Residence Initiative
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => libh-beir-2018
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2018-08-22 20:10:08
                    [post_modified_gmt] => 2018-08-22 20:10:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/?p=3046
                    [menu_order] => 114
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 3597
                    [post_author] => 3
                    [post_date] => 2020-08-11 11:07:26
                    [post_date_gmt] => 2020-08-11 11:07:26
                    [post_content] => Brookhaven National Laboratory opened its new cryo-electron microscopy center, the Laboratory for BioMolecular Structure (LBMS), with an initial focus on COVID-19-related research through an open proposal call. This state-of-the-art research center offers researchers access to advanced cryo-electron microscopes (cryo-EM) for single particle analysis of proteins and macromolecular complexes, as well as cryo-electron tomography (cryo-ET) of cells and tissues.

LBMS currently has two cryo-electron microscopes—funded by NY State’s Empire State Development—and the facility has space for additional microscopes to enhance its capabilities in the future.

Researchers working on non-proprietary COVID-19-related studies can request remote access to the instruments free of charge by submitting a COVID-19 Rapid Access proposal. For questions regarding the LBMS facility or the call for COVID-19 Rapid Access proposals, please contact Liguo Wang at lwang1@bnl.gov.

 
                    [post_title] => New BNL Cryo-Electron Microscopy Center Open for Remote Access
                    [post_excerpt] => Researchers working on non-proprietary COVID-19-related studies can request remote access to the instruments free of charge. 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => new-bnl-cryo-electron-microscopy-center-open-for-remote-access
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2020-09-14 14:22:27
                    [post_modified_gmt] => 2020-09-14 14:22:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3597
                    [menu_order] => 58
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 2064
                    [post_author] => 3
                    [post_date] => 2015-12-07 20:15:00
                    [post_date_gmt] => 2015-12-07 20:15:00
                    [post_content] => Accelerating Biomedical Discoveries for Commercialization

STONY BROOK, N.Y. – December 7, 2015 - The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced today the recipients of the first technology development grants awarded by the Hub. Thirteen awards totaling $900,000 were granted to applicants from Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory.

The LIBH technology development grants are a multi-tiered funding initiative aimed at collectively contributing to a pipeline of commercially promising biomedical technology in the region. The three funding initiatives include Feasibility, Proof of Concept and Commercialization awards.

Feasibility awards are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications of an existing technology.  Proof of Concept Awards provide targeted, milestone driven support for proof of concept research, development, testing, and analysis of existing intellectual property. The final tier, Commercialization Awards, provide targeted, milestone-driven support for a subset of projects with existing intellectual property where additional investment will clearly advance the technology to a major value inflection point for commercialization.

The grants awarded this cycle will support technologies developed across multiple disciplines including pharmacology, biomedical engineering, chemistry, and microbiology. Among the award recipients were two post-doctoral researchers. Of the thirteen grants awarded, eight were Feasibility awards and five were Proof of Concept Awards. The recipients of this round of awards are:

Feasibility awards

    
	
  • Targeting Pathogenic Viral Infections with First-In-Class Viral Budding Inhibitors - Dr. Carol Carter
    • 
	
  • Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer - Dr. Michael Frohman
    • 
	
  • Novel miR-129 Based Therapeutics for Colon Cancer - Dr. Jingfang Ju
    • 
	
  • Fast Hybrid Approach For Determination of Structure of Therapeutic Protein Complexes - Dr. Dima Kosakov
    • 
	
  • Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs - Dr. Gabriel Pagnotti
    • 
	
  • Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration - Dr. Yixian Qin
    • 
	
  • LDL as Biomarker for Childhood Tuberculosis (TB) - Dr. Xinxin Yang
    • 


Proof of Concept awards

    
	
  • A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology - Dr. Marcous Abboud
    • 
	
  • Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams - Dr. Avraham Dilmanian
    • 
	
  • NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight (TOF) Positron Emission Tomography (PET) - Dr. Amirhossein Goldan
    • 
	
  • Azasteroids for Combination Anti-TB Therapy - Dr. Nicole Sampson
    • 
	
  • A Novel Glioblastoma Drug – Oncolytic Virus PV1-Mono-Cre - Dr. Eckard Wimmer
    • 


​“We are excited to see such a robust and diverse portfolio of early stage technologies supported through the LIBH and NIH-REACH consortium,” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “We are hopeful that this investment by the federal and state government, as well as SBU, CSHL and BNL, will foster and accelerate the translation of these technologies from the bench to the bed side, and help attract further investment from the industrial and financial sectors.”

The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.
                    [post_title] => Long Island Bioscience Hub Announces Funded Projects
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => long-island-bioscience-hub-announces-funded-projects
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2016-03-29 20:18:36
                    [post_modified_gmt] => 2016-03-29 20:18:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/?p=2064
                    [menu_order] => 195
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [post_count] => 4
    [current_post] => -1
    [before_loop] => 1
    [in_the_loop] => 
    [post] => WP_Post Object
        (
            [ID] => 4439
            [post_author] => 3
            [post_date] => 2024-07-30 15:29:07
            [post_date_gmt] => 2024-07-30 19:29:07
            [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.





The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development. 





Read more about IAMBIC and their recent funding here.


            [post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
            [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2024-11-19 10:50:15
            [post_modified_gmt] => 2024-11-19 15:50:15
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://centerforbiotechnology.org/?p=4439
            [menu_order] => 0
            [post_type] => post
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 261
    [max_num_pages] => 87
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 
    [is_tax] => 
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 1
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

)

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

July 30, 2024

More Information

Long Island Bioscience Hub Appoints Additional BioEntrepreneurs-In-Residence

August 22, 2018

More Information

New BNL Cryo-Electron Microscopy Center Open for Remote Access

August 11, 2020

More Information

Long Island Bioscience Hub Announces Funded Projects

December 7, 2015

More Information